{
    "clinical_study": {
        "@rank": "99077", 
        "acronym": "ALLO-WT1", 
        "arm_group": {
            "arm_group_label": "immune therapy", 
            "arm_group_type": "Experimental", 
            "description": "6 administration every 2 weeks of intra-muscular 200 micrograms of  protein recwt1-A10+AS01B  at week 1, 3, 5, 7, 9 and 11."
        }, 
        "brief_summary": {
            "textblock": "Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent\n      allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after\n      reduced-intensity conditioning regimen.\n\n      If WT1 expression is detectable on tumor cells, they will receive an immune therapy 60 days\n      after allograft.\n\n      6 administrations every 2 weeks of the protein recwt1-A10+AS01B will be administrated.\n\n      The safety and immunological efficacy of this immune therapy after hematopoietic stem cells\n      transplantation with reduced intensity conditioning will be evaluated."
        }, 
        "brief_title": "Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Chronic Myeloid Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients older than 18 and younger than 65 years.\n\n          2. Karnofsky \u2265 70 %.\n\n          3. Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, who\n             underwent allogeneic stem cell transplantation from HLA-identical donor (related or\n             unrelated) after reduced-intensity conditioning regimen.\n\n          4. Patients in morphologic complete remission at the time of transplantation.\n\n          5. WT1 expression detectable on tumor cells.\n\n          6. Expected life duration more than 6 months.\n\n          7. Creatinine clearance \u2265 50 ml/min\n\n          8. Bilirubinemia < 1.5N and ASAT < 2.5N.\n\n          9. Women of childbearing age: negative pregnancy test and effective contraception for at\n             least 30 days before vaccinal immunotherapy (the same contraceptive method must be\n             continued at least 2 months after the last vaccine infusion).\n\n         10. Membership of a social security scheme or beneficiary of such a regime.\n\n         11. Signed inform consent.\n\n        Exclusion Criteria:\n\n          1. Patients with severe and uncontrolled affections, especially active graft-versus-host\n             disease requiring steroid treatment (>0.3 mg/kg/j) and/or Mycophenolate mofetil.\n\n          2. Pregnant or lactating women.\n\n          3. HIV seropositive patients.\n\n          4. Autoimmune disease (Lupus, multiple sclerosis, Chron disease\u2026)\n\n          5. Previous history of allergic state which could be potentially compound by a component\n             of the vaccinal immunotherapy.\n\n          6. Patients who received (or are planned to receive) another experimental treatment\n             within 30 days following the first infusion of the experimental drug of this\n             protocol.\n\n          7. Previous history of another cancer, except if considered as probably cured by the\n             investigator.\n\n          8. Patients deprived of liberty, or under guardianship."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819558", 
            "org_study_id": "ALLO-WT1/IPC 2011-006"
        }, 
        "intervention": {
            "arm_group_label": "immune therapy", 
            "intervention_name": "recwt1-A10+AS01B", 
            "intervention_type": "Biological", 
            "other_name": "immune therapy"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute myeloid leukemia", 
            "chronic myeloid leukemia", 
            "myelodysplastic syndrome", 
            "allograft", 
            "WT1 expression"
        ], 
        "lastchanged_date": "December 31, 2013", 
        "link": {
            "description": "official web site of the sponsor", 
            "url": "http://www.institutpaolicalmettes.fr/"
        }, 
        "location": {
            "contact": {
                "last_name": "Didier BLAISE, MD PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Marseille", 
                    "country": "France", 
                    "zip": "13009"
                }, 
                "name": "Institut Paoli-Calmettes"
            }, 
            "investigator": {
                "last_name": "Didier BLAISE, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Etude Phase I/II d'immunoth\u00e9rapie Par prot\u00e9ine recWT1-A10+AS01B apr\u00e8s Greffe allog\u00e9nique de Cellules Souches", 
        "overall_contact": {
            "email": "drci.up@ipc.unicancer.fr", 
            "last_name": "Agn\u00e8s BOYER CHAMMARD, MD", 
            "phone": "+33491223778"
        }, 
        "overall_official": {
            "affiliation": "Institut Paoli-Calmettes", 
            "last_name": "Didier BLAISE, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dose limit toxicity (adverse event according to CTCAE V4.0)", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The specific WT1 antibody induced by the vaccination will be evaluated by the technic ELISA in UE/ml.", 
            "measure": "immune response", 
            "safety_issue": "No", 
            "time_frame": "up to 60 weeks after treatment"
        }, 
        "source": "Institut Paoli-Calmettes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Paoli-Calmettes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}